Clinical evolution of neuroretinitis in Parry-Romberg syndrome

A 16-year-old girl with Parry-Romberg syndrome presented with monolateral exudative neuroretinitis and retinal telangiectasis that had been observed for 42 months. She was treated with immunosuppressive therapy with A-cyclosporine for 1 year, followed by laser treatment of telangiectasis. Her visual...

Full description

Saved in:
Bibliographic Details
Published inJournal of pediatric ophthalmology and strabismus Vol. 45; no. 2; pp. 125 - 126
Main Authors de Crecchio, Giuseppe, Forte, Raimondo, Strianese, Diego, Rinaldi, Michele, D'Aponte, Antonella
Format Journal Article
LanguageEnglish
Published United States SLACK INCORPORATED 01.03.2008
Subjects
Adolescent
Combined Modality Therapy
Cyclosporine - therapeutic use
Facial Hemiatrophy - complications
Female
Fluorescein Angiography
Humans
Immunosuppressive Agents - therapeutic use
Laser Coagulation
Retinitis - diagnosis
Retinitis - etiology
Retinitis - therapy
Telangiectasis - diagnosis
Telangiectasis - etiology
Telangiectasis - therapy
Online AccessGet full text

Cover

More Information
Summary:A 16-year-old girl with Parry-Romberg syndrome presented with monolateral exudative neuroretinitis and retinal telangiectasis that had been observed for 42 months. She was treated with immunosuppressive therapy with A-cyclosporine for 1 year, followed by laser treatment of telangiectasis. Her visual acuity improved from 20/200 to 20/70 in 1 year with a reduction of neuroretinal exudation. Laser treatment resulted in a further improvement of visual acuity to 20/40. Clinical findings remained unchanged during 2 years of follow-up. The association of immunosuppressive treatment and laser therapy may improve neuroretinal disease in the presence of Parry-Romberg syndrome.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0191-3913
1938-2405
DOI:10.3928/01913913-20080301-04